Targeted re-sequencing of cancer-related genes from matched FFPE and Fresh-Frozen tumor samples using the Illumina sequencing platform

Marina Bibikova¹, Jeremy Chien², Vincent Ho¹, Craig April¹, Sarah Munchel¹, Joseph Cottrell¹, Sarah Munchel¹, Sa Megan Manion³, Jonathan Liu³, Eric Wieben², Lynn Hartmann², Kim Kalli², Viji Shridhar ², and Jian-Bing Fan¹.

1. Introduction

High throughput sequencing technologies open up a new dimension in cancer genomics by enabling the characterization of cancer genomes at base-pair resolution. The large-scale genomics projects are mostly utilizing fresh-frozen biospecimens in their studies to characterize cancer genomes. Unlike fresh-frozen samples, archived formalin-fixed paraffin-embedded (FFPE) tissues are more readily accessible, and are often associated with known clinical outcomes and more complete clinical annotations. However, sequencing library preparation methods need to be further optimized with regard to applicability to FFPE samples. To test whether next-generation sequencing technologies could report accurate sequencing results and overcome previously reported artifacts associated with formalin fixation, we compared whole-genome and targeted enrichment DNA sequencing data obtained from five FFPE tumor samples for which matching frozen tissues were available. Using 1 µg of genomic DNA as input material and a modified TruSeq® sample preparation protocol, we successfully generated sequencing libraries. We prepared a custom enrichment pool that targeted exons from 215 cancer-related genes and utilized this pool to perform the pull-down and sequencing of approximately 1.3 Mb region with average 400x coverage depth to test if deep sequencing would help in validation of tumor-specific somatic mutations. We used the Illumina sequence analysis pipeline and the Windowsbased second generation DNA sequencing software NextGENe to analyze the data and identify sequence variations that are different from the human reference genome. CNV detection was overall higher among FFPE samples compared with fresh-frozen samples, demonstrating that tissue processing can impact sequencing data

quality. We obtained good concordance in variant calls between matched FFPE and fresh-frozen samples. Discordant variant calls were mainly due to low depth of coverage in the regions where variant calls were made.

Improvements to DNA sequencing methods for archived samples will significantly enhance cancer research and will result in more reliable prediction of individual cancer therapies.



© 2012 Illumina, Inc. All rights reserved.

¹Illumina, Inc., San Diego, California; ²Mayo Clinic, Rochester, Minnesota; ³Softgenetics, LLC, State College, Pennsylvania

3. Data Analysis

- In addition to CASAVA 1.8 data analysis pipeline, we used Windows-based NextGENe DNA sequencing software to analyze the data and identify sequence variations that are different from human reference genome.
- Fastq files from CASAVA 1.8 output were processed into FASTA format by NextGENe software. During this conversion, reads not meeting preset QC criteria were filtered out and not used in read mapping to the human reference genome.
- SNP/ Indel Discovery Application was used for further analysis.
- Mutation reports were generated in the NextGENe Viewer and analyzed in pairs through the JMP statistical analysis program, as well as PERL and MATLAB scripts to determine the number of concordant and discordant calls between matched samples.
- Concordant calls were defined as calls with matching genotypes in matched samples.
- Discordant calls were made where there was a difference in variant call between the matched samples at the same reference position.



-			
Sample_121	6498	76	98.84
Sample_119	6456	63	99.03
Sample_102	6088	78	98.73
Sample_123	6418	87	98.66
Sample 127	6491	57	99.13

Discordant variant calls are mainly due to low coverage of reads in the region where variant calls are being made.

5. Concordance analysis



- We called variants if variant frequency was > 20% in FF or FFPE samples.
- Variant frequency < 20% is not included in the graphs.</p>







6. BRCA2 mutation in FF-121 and matched FFPE samples



An example of SNV discovered through WGS of the FF-121 sample. The same SNV can be detected in both FF and FFPE samples after targeted enrichment

7. Challenges with structural variant detection



Insert size is shorter and more variable in FFPE samples Accurate indel detection in FFPE samples is challenging

Elevated error rate is often detected at the beginning of Read 2 in FFPE samples only

9. Effect of Cytosine Deamination ං 👚 🛷 🔳 - chr 19:40,741,805-40,741,91 pii gii gi2 gi3.11 gi3.12 gi3.2 gi3.31 gi3.33 gi3.41 -121 Coverage -121 sorted.bam FPE-121 Coverage FPE-121 sorted.bam D K K L L G A L L S K A E P S L T R P F R I E E M L I L E F L R E H D Q Seq Genes chr 19:40741860 Earlier reports indicate that most of the artificial mutations recorded in DNA extracted from FFPE are either C-T or G-A transitions. C->T transition (result of Cytosine deamination) is present in FFPE but not in the matched FF sample 10. Depth and uniformity of coverage p12 p11.2 q11 32,902 kb 32,904 kb 121 Coverage 121 sorted.bam FPE-121 Coverage FFPE-121 sorted.bam $\rightarrow \rightarrow \rightarrow \rightarrow \rightarrow$ RefSeq Genes racks loaded After targeted pool down, samples were sequenced to 400x depth on average Large number of PCR duplicates result in overall lower unique coverage in FFPE samples 11. Conclusions Overall good concordance in variant calls was observed between FF and FFPE samples FFPE samples can be used for biomarker validation in clinical studies Challenges with FFPE analysis: Increased number of false positives due to C->T deamination Lower coverage uniformity

- needed for robust variant calling

Illumina, illuminaDx, BaseSpace, BeadArray, BeadXpress, cBot, CSPro, DASL, DesignStudio, Eco, GAIIx, Genetic Energy, Genome Analyzer, GenomeStudio, GoldenGate, HiScan, HiSeq, Infinium, iSelect, MiSeq, Nextera, Sentrix, SeqMonitor, Solexa, TruSeq, VeraCode, the pumpkin orange color, and the Genetic Energy streaming bases design are trademarks or registered trademarks of Illumina, Inc. All other brands and names contained herein are the property of their respective owners







drr 13:32,901,226-32,920,224 Go 👚 🤣 🔲 🔤 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
q12.12 q12.3 q13.3 q14.12 q14.3 q21.2 q21.32 q22.1 q31.1 q31.2 q32.1 q33.1 q33.3
18 kb −
الم
BRCA2

Elevated error rate at the start of read 2

Protocol optimization may further improve data quality Data analysis pipeline optimized for FFPE samples is

